Business

Notice of Results & Investor Presentation

Notice of Results & Investor Presentation.

articleEco Animal Health Group PlcJuly 5, 20233/company/eco-animal-health-group-plc/news/notice-of-results-and-investor-presentation-154
Notice of Results & Investor Presentation

About this update from Eco Animal Health Group Plc

[{"type":"text","content":"\n\n5 July 2023\nECO Animal Health Group plc\n(''ECO\", the \"Company\" or the \"ECO Group\")\n(AIM: EAH)\nNotice of Results & Investor Presentation\nECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will issue its results for the year ended 31 March 2023 on Monday 10 July 2023.\nInvestor Presentation\nDavid Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the company's FY Results for the period ended 31 March 2023. The online presentation will take place on Wednesday 12 July at 2.30pm UK time.\nThis event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it. Please register using the following link:\nhttps://www.equitydevelopment.co.uk/news-and-events/ecoanimalhealth-fyresultspresentation-12july2023\n \nFor further information please contact:\n\n\n\nECO Animal Health Group plc\nDavid Hallas (CEO)\nChristopher Wilks (CFO)\n \n\n\n020 8447 8899\n \n\n\n\n\n \nIFC Advisory\nGraham Herring\nZach Cohen\n \n\n\n \n020 3934 6630\n \n\n\n\n\n \nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhil Davies\nGeorge Tzimas\n\n\n \n020 7496 3000\n\n\n\n\n \nInvestec (Joint Broker)\nGary Clarence\nLydia Zychowska\nCarlo Spingardi\n\n\n \n020 7597 5970\n \n \n \n\n\n\n \n\n\n\nEquity Development\nHannah Crowe\nMatt Evans\n\n\n020 7065 2692\n\n\n\n \nAbout ECO Animal Health\nECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development (\"R&D\") for new products, particularly vaccines, and seeking to in-license new products.\n\n","length":5378,"tagName":"div"}]

More updates from Eco Animal Health Group Plc